What is the current stock price of Ernexa Therapeutics Inc. (ERNA)?

As of the latest market data, Ernexa Therapeutics Inc. (ERNA) is trading at $0.20. The stock has seen a loss of -5.34% today.

Does Ernexa Therapeutics Inc. (ERNA) pay a dividend?

Based on current data, Ernexa Therapeutics Inc. does not have a confirmed active dividend policy.

What is the market cap of Ernexa Therapeutics Inc.?

The current market capitalization of Ernexa Therapeutics Inc. (ERNA) is approximately unavailable.

ERNA

Ernexa Therapeutics Inc.·Healthcare

0.20

5.337%(−0.01)

Market Closed

0.21

9.175%(+0.02)

After Hours

Last Updated: — ET

52W L: $0.1852W H: $4.05

ERNA NEWS

globenewswire.com

Mar 31

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer

defenseworld.net

Mar 14

Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) saw a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 247,054 shares, a growth of 136.9% from the February 12th total of 104,299 shares. Currently, 3.3% of the company's shares are sold short. Based on an

defenseworld.net

Mar 4

Comparing Aditxt (NASDAQ:ADTX) & Ernexa Therapeutics (NASDAQ:ERNA)

Ernexa Therapeutics (NASDAQ: ERNA - Get Free Report) and Aditxt (NASDAQ: ADTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Insider and Institutional Ownership 70.6% of Ernexa Therapeutics

defenseworld.net

Feb 24

Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 11.4% – Time to Sell?

Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) shares were down 11.4% during trading on Monday. The company traded as low as $0.2703 and last traded at $0.2703. Approximately 1,070,042 shares were traded during trading, a decline of 65% from the average daily volume of 3,040,254 shares. The stock had previously closed at $0.3051.

globenewswire.com

Feb 20

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET

globenewswire.com

Feb 6

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of $0.50 per share (or per common stock equivalent in lieu thereof) and accompanying warrant.

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

1991-08-29

Beta

6.85

Websitewww.ernexatx.com↗